TD Ameritrade Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TD Ameritrade Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-47	Closed	-$17K	–	497
2023 Q2	$17K	Sell	47 -19	-29%	-$6.4K	﹤0.01%	301
2023 Q1	$21K	Sell	66 -31	-32%	-$9.3K	﹤0.01%	302
2022 Q4	$28K	Buy	+97	New	+$29.6K	﹤0.01%	297
2022 Q3	–	Sell	-268	Closed	-$76K	–	635
2022 Q2	$76K	Sell	268 -253	-49%	-$67.7K	﹤0.01%	268
2022 Q1	$136K	Sell	521 -30	-5%	-$7.12K	﹤0.01%	267
2021 Q4	$121K	Buy	+551	New	+$107K	﹤0.01%	279
2021 Q3	–	Sell	-457	Closed	-$92K	–	704
2021 Q2	$92K	Buy	+457	New	+$95.6K	﹤0.01%	288
2019 Q3	–	Sell	-21	Closed	-$4K	–	724
2019 Q2	$4K	Hold	21	–	–	﹤0.01%	523
2019 Q1	$4K	Sell	21 -51	-71%	-$9.42K	﹤0.01%	479
2018 Q4	$12K	Buy	72 +47	+188%	+$8.14K	﹤0.01%	334
2018 Q3	$5K	Buy	25 +5	+25%	+$890	﹤0.01%	409
2018 Q2	$3K	Buy	+20	New	+$3.1K	﹤0.01%	318

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Ameritrade Investment Management's VRTX Position: Q3 2023 in Review

TD Ameritrade Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 47 shares — an estimated $17K sold.

TD Ameritrade Investment Management first reported a position in VRTX in Q2 2018 and held it in 12 quarters. The position peaked at $136K in Q1 2022. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

TD Ameritrade Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
TD Ameritrade Investment Management sold 47 Vertex Pharmaceuticals shares in Q3 2023, an estimated $17K.
TD Ameritrade Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2018 and held it in 12 quarters.
TD Ameritrade Investment Management's Vertex Pharmaceuticals position peaked at $136K in Q1 2022.
1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q3 2023.